2023 2023 Nucleosides, Nucleotides and Oligonucleotides GRC & GRS

2023 2023 核苷、核苷酸和寡核苷酸 GRC

• 批准号: 10609239
• 负责人: Katherine L Seley-Radtke
• 金额: $ 0.7万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-10 至 2023-07-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10609239
• 关键词: 2019-nCoV; Acute; Address; African American; Antibiotics; Antiviral Agents; Attitude; Basic Science; Biology; Biomedical Research; COVID-19 pandemic; Calibration; Chemicals; Chemistry; Clinic; Collaborations; Communicable Diseases; Communities; Coronavirus; Creativeness; Dedications; Development; Diagnostic; Disease; Effectiveness; Employment Opportunities; Environment; Ethnic Origin; Ethnic Population; Fees; Female; Funding; Funding Agency; Future; Gender; Genetic Diseases; Goals; Government; HIV/AIDS; Health; Hepatitis C; Hour; Human; Human Biology; Industrialization; Industry; Institution; International; Knowledge; Learning; Light; Marketing; Mentors; Minority; Nucleic Acids; Nucleosides; Nucleotides; Occupations; Oligonucleotides; Oral; Organizational Objectives; Participant; Pharmaceutical Preparations; Postdoctoral Fellow; Purine Nucleosides; RNA; Recording of previous events; Research; Research Personnel; Science; Scientist; Spinal Muscular Atrophy; Structural Chemistry; Students; Tenofovir; Therapeutic; Underrepresented Minority; Underrepresented Populations; Woman; Zidovudine; career; clinical application; clinical translation; coronavirus therapeutics; current pandemic; drug development; drug discovery; effective therapy; epitranscriptome; improved; insight; interest; meetings; member; men; new technology; nucleic acid-based therapeutics; posters; programs; recruit; remdesivir; small molecule; social group; success; symposium; tool; undergraduate student; vaccine development

PROJECT SUMMARY/ABSTRACT This proposal seeks funding to support the 2023 Nucleosides, Nucleotides and Oligonucleotides (NNO) Gordon Research Conference and associated Gordon Research Seminar. This will be the 21st edition of this conference, which was initiated in 1976. Throughout its history, this conference has addressed topics that are directly related to the fundamental science of human biology and the treatment of disease. Nucleosides and nucleotides have been extremely effective drugs, most notably antivirals such as AZT and Harvoni, for the treatment of HIV/AIDS and hepatitis C, respectively. Meanwhile, the field has broadened to include oligonucleotides as biomedical research tools and, increasingly, therapeutics for genetic diseases, such as Spinraza, which treats spinal muscular atrophy. There are four specific aims for the conference: (1) facilitate scientists in the field to learn about the latest advances in academic, industrial and government research labs; (2) introduce new scientists to the topic; (3) provide networking opportunities to build relationships and collaborations as well as matching students with potential future employers; (4) enhance the diversity of our field by providing speaking and discussion leader opportunities to women and members of under-represented ethnic groups. These specific aims will contribute to long-term goal of the conference, which is to have a broad and sustainable impact on both basic science and clinical translation of nucleosides, nucleotides and oligonucleotides in order to improve human health. The 2023 edition of the conference will include sessions dedicated to (1) emerging therapeutics for coronaviruses, (2) small molecules - chemistry & applications, (3) chemical biology and nucleic acid based diagnostics, (4) oligonucleotide and nucleic acid therapeutics, (5) structural chemistry of nucleic acids, and (6) RNA-targeting and epitranscriptomes. (Other sessions will be organized after final invitations have been accepted and speakers have submitted their titles.) The PI solicited nominations from experts in the field, emphasizing the desire to identify members of under-represented groups and young scientists as potential speakers. Of the 31 invited speakers, 15 are women, including three African-American females; the average GRC has 30% female speakers. In addition, currently we have six speakers from underrepresented minorties. The affiliated Gordon Research Seminar will feature oral presentations by students and postdocs, a panel discussion with established scientists in the field, and the opportunity to create a sense of community prior to the start of the GRC. In addition, the GRC “Power Hour” will take place during one afternoon and provides a forum in which all participants can discuss the unique challenges faced by women in science. Thus, while the cutting edge science described during the oral sessions will undoubtedly inspire others to move their own research forward in new and creative ways, the GRS, Power Hour and other efforts to support women, minorities and young scientists in general will strengthen the field and its impact on human health for decades to come.

项目摘要/摘要 这项提案寻求资金支持2023年的核苷、核苷酸和寡核苷酸(NNO)戈登 研究会议和相关的戈登研究研讨会。这将是第21届大会， 它是在1976年发起的。在整个历史上，这次会议都讨论了与 人类生物学和疾病治疗的基础科学。核苷和核苷酸都有 是治疗艾滋病毒/艾滋病的极其有效的药物，最著名的是AZT和哈沃尼等抗病毒药物 和丙型肝炎。与此同时，这一领域已经扩大到包括作为生物医学的寡核苷酸 研究工具，以及越来越多的遗传病疗法，如治疗脊柱疾病的Spinraza 肌肉萎缩。 这次会议的具体目的有四个：(1)促进该领域的科学家了解最新 学术、工业和政府研究实验室的进展；(2)引入新的科学家；(3) 提供建立关系和协作以及为学生牵线搭桥的网络机会 潜在的未来雇主；(4)通过提供演讲和讨论领袖来增强我们领域的多样性 向妇女和代表性不足的族裔群体成员提供机会。这些具体目标将有助于 会议的长期目标是对基础科学和 核苷、核苷酸和寡核苷酸的临床翻译，以改善人类健康。 2023年的会议将包括专门讨论(1)新兴疗法的会议 冠状病毒，(2)小分子化学及应用，(3)化学生物学和核酸 诊断学，(4)寡核苷酸和核酸治疗学，(5)核酸的结构化学，和(6) RNA靶向和表位转录。(其他会议将在最终邀请完成后组织 被接受，演讲者已经提交了他们的标题。)国际和平研究所向该领域的专家征集提名， 强调希望将代表性不足群体的成员和年轻科学家确定为有潜力的 扬声器。在31位受邀的演讲者中，有15位是女性，其中包括3位非裔美国女性；平均 GRC有30%的女性发言人。此外，目前我们有6名发言者来自代表性不足的少数群体。 附属的戈登研究研讨会将由学生和博士后进行口头报告，这是一个小组 与该领域的知名科学家进行讨论，并有机会在会议之前创造社区意识 GRC的开始。此外，GRC的“动力一小时”将在一个下午举行，并提供一个论坛 所有参与者都可以讨论女性在科学领域面临的独特挑战。因此，在切割的同时 在口头会议中描述的边缘科学无疑将激励其他人推动他们自己的研究 以新的和创造性的方式推进GRS、Power Hour和其他支持妇女、少数群体和 总的来说，年轻科学家将在未来几十年加强这一领域及其对人类健康的影响。